Patents by Inventor Mitsutoshi TOMINAGA

Mitsutoshi TOMINAGA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENT FOR PREVENTING OR AMELIORATING PRURITUS
    Publication number: 20240115546
    Abstract: A novel target molecule for pruritus was found, and a novel means for eliminating pruritus is provided.
    Type: Application
    Filed: November 24, 2023
    Publication date: April 11, 2024
    Applicant: KAO CORPORATION
    Inventors: Tomohiro MATSUMOTO, Masafumi YOKOTA, Junko ISHIKAWA, Mitsutoshi TOMINAGA, Kenji TAKAMORI
  • ITCH TREATMENT USING A COMBINATION OF NEUROKININ-1, GASTRIN RELEASING PEPTIDE, AND GLUTAMATE RECEPTOR ANTAGONISTS
    Publication number: 20180221435
    Abstract: Methods, and compositions are provided for inhibition of histamine and non-histamine dependent itch signal transmission or scratch behavior. In one aspect, the present invention further comprises administering to the subject an inhibitor of histamine-dependent itch signal transmission. In some cases, the inhibitor of histamine independent itch signal transmission comprises an NK-1 receptor antagonist or the inhibitor of histamine independent itch signal transmission comprises a GRP receptor antagonist. In some cases, the method comprises administering two inhibitors of histamine independent itch signal transmission. For example, the inhibitors of histamine independent itch signal transmission can comprise an NK-1 receptor antagonist and a GRP receptor antagonist. In another embodiment, the invention provides a method of treating itch comprising administering to a subject suffering from itch an NK-1 receptor antagonist, a GRP receptor antagonist, and an AMPA receptor antagonist.
    Type: Application
    Filed: January 16, 2018
    Publication date: August 9, 2018
    Inventors: Earl Carstens, Tasuku AKIYAMA, Mitsutoshi TOMINAGA
  • THERAPEUTIC OR PROPHYLACTIC AGENT FOR ITCHING SKIN DISEASES
    Publication number: 20170281727
    Abstract: An antimicrobial peptide LL-37 has an action to promote expression of a nerve repulsion factor Sema3A. LL-37 is a peptide composed of the C-terminal 37 residues of human cathelicidin hCAP18. Use of this antimicrobial peptide enables normalization of expression of axon guidance molecules such as nerve repulsion factor in lesions of pruritic dermatoses including atopic dermatitis and xeroderma, and thus enables alleviation of pruritus and amelioration of skin lesions.
    Type: Application
    Filed: September 2, 2015
    Publication date: October 5, 2017
    Inventors: Yoshie Umehara, Yayoi Kamata, Mitsutoshi Tominaga, Francois Niyonsaba, Kenji Takamori
  • NEW ITCH TREATMENT USING A COMBINATION OF NEUROKININ-1, GASTRIN RELEASING PEPTIDE, AND GLUTAMATE RECEPTOR ANTAGONISTS
    Publication number: 20150320827
    Abstract: Methods, and compositions are provided for inhibition of histamine and non-histamine dependent itch signal transmission or scratch behavior. In one aspect, the present invention further comprises administering to the subject an inhibitor of histamine-dependent itch signal transmission. In some cases, the inhibitor of histamine independent itch signal transmission comprises an NK-1 receptor antagonist or the inhibitor of histamine independent itch signal transmission comprises a GRP receptor antagonist. In some cases, the method comprises administering two inhibitors of histamine independent itch signal transmission. For example, the inhibitors of histamine independent itch signal transmission can comprise an NK-1 receptor antagonist and a GRP receptor antagonist. In another embodiment, the invention provides a method of treating itch comprising administering to a subject suffering from itch an NK-1 receptor antagonist, a GRP receptor antagonist.
    Type: Application
    Filed: January 16, 2014
    Publication date: November 12, 2015
    Inventors: Earl CARSTENS, Tasuku AKIYAMA, Mitsutoshi TOMINAGA